1. severe co-morbidity with life expectancy \<3 months according to investigators assessment 2. (aspartate transaminase/ alanine aminotransferase) asat/alat \> 5 times the upper limit of normal 3. acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. known intolerance to the available study drugs 5. pregnancy, possible pregnancy or breast feeding 6. any reason why, in the opinion of the investigators, the patient should not participate 7. subject participates in a potentially confounding drug or device trial during the course of the study 8. prolonged qt interval (\>450 ms)

1. severe co-morbidity with life expectancy \<3 months according to investigators assessment 2. (aspartate transaminase/ alanine aminotransferase) asat/alat \> 5 times the upper limit of normal 3. acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. known intolerance to the available study drugs 5. pregnancy, possible pregnancy or breast feeding 6. any reason why, in the opinion of the investigators, the patient should not participate 7. subject participates in a potentially confounding drug or device trial during the course of the study 8. prolonged qt interval (\>450 ms)

severe co-morbidity with life expectancy <3 months according to investigators assessment (aspartate transaminase/ alanine aminotransferase) asat/alat > 5 times the upper limit of normal acute co-morbidity within 7 days before inclusion such as myocardial infarction known intolerance to the available study drugs pregnancy, possible pregnancy or breast feeding any reason why, in the opinion of the investigators, the patient should not participate subject participates in a potentially confounding drug or device trial during the course of the study prolonged qt interval (>450 ms)

severe co-morbidity with life expectancy <3 months according to investigators assessment (aspartate transaminase/ alanine aminotransferase) asat/alat > 5 times the upper limit of normal acute co-morbidity within 7 days before inclusion such as myocardial infarction known intolerance to the available study drugs pregnancy, possible pregnancy or breast feeding any reason why, in the opinion of the investigators, the patient should not participate subject participates in a potentially confounding drug or device trial during the course of the study prolonged qt interval (>450 ms)

1. severe co-morbidity with life expectancy <3 months according to investigators assessment 2. (aspartate transaminase/ alanine aminotransferase) asat/alat > 5 times the upper limit of normal 3. acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. known intolerance to the available study drugs 5. pregnancy, possible pregnancy or breast feeding 6. any reason why, in the opinion of the investigators, the patient should not participate 7. subject participates in a potentially confounding drug or device trial during the course of the study 8. prolonged qt interval (>450 ms)

1. severe co-morbidity with life expectancy <3 months according to investigators assessment 2. (aspartate transaminase/ alanine aminotransferase) asat/alat > 5 times the upper limit of normal 3. acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. known intolerance to the available study drugs 5. pregnancy, possible pregnancy or breast feeding 6. any reason why, in the opinion of the investigators, the patient should not participate 7. subject participates in a potentially confounding drug or device trial during the course of the study 8. prolonged qt interval (>450 ms)